Infliximab biosimilar for psoriasis

Remsima (infliximab), an anti-inflammatory biologic medicine biosimilar to the anti-TNF Remicade (infliximab), has been launched in the UK


Remsima (infliximab), an anti-inflammatory biologic medicine biosimilar to the anti-TNF Remicade (infliximab), has been launched in the UK with a licence for a range of conditions, including psoriasis.
Remsima has been specifically developed to be highly similar to Remicade, which binds and blocks TNF alpha, an inflammatory substance that is overproduced in some inflammatory conditions.
Remsima was authorised by the European Medicines Agency after undergoing a comparability assessment versus Remicade. This included clinical trials involving 850 patients in 20 countries, which the manufacturers claim showed no clinically meaningful differences between the two medicines.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab)
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more